Systemic Factors Associated with Treatment Response in Diabetic Macular Edema

Purpose. To identify systemic factors that may influence the response to anti-VEGF therapy in patients with diabetic macular edema (DME). Methods. 35 patients undergoing anti-VEGF injections for centre-involving DME were studied in this prospective observational study. The primary outcome was change...

Full description

Bibliographic Details
Main Authors: Wendy Meihua Wong, Caroline Chee, Mayuri Bhargava, Charmaine Chai, Hazel Lin, Paul Zhao, Erlangga Ariadarma Mangunkusumo, Thet Naing, Yew Sen Yuen, Tien Yin Wong, Xinyi Su, Gopal Lingam
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2020/1875860
id doaj-3383bdfa7365423b9ae73f002a55f6ad
record_format Article
spelling doaj-3383bdfa7365423b9ae73f002a55f6ad2020-11-25T03:03:36ZengHindawi LimitedJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/18758601875860Systemic Factors Associated with Treatment Response in Diabetic Macular EdemaWendy Meihua Wong0Caroline Chee1Mayuri Bhargava2Charmaine Chai3Hazel Lin4Paul Zhao5Erlangga Ariadarma Mangunkusumo6Thet Naing7Yew Sen Yuen8Tien Yin Wong9Xinyi Su10Gopal Lingam11National University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporeNational University Hospital, SingaporePurpose. To identify systemic factors that may influence the response to anti-VEGF therapy in patients with diabetic macular edema (DME). Methods. 35 patients undergoing anti-VEGF injections for centre-involving DME were studied in this prospective observational study. The primary outcome was change in macular thickness one month after treatment, measured using spectral-domain optical coherence tomography (OCT). At baseline, information on various systemic factors was collected including glycosylated hemoglobin (HbA1c), serum VEGF levels, lipid profile and markers of renal function, and blood pressure. Thirty-three of the 35 patients were included in this study. Nonparametric statistical tests were used for the analysis of the data in view of the nonnormal distribution of the outcome variables. Multivariate analysis was performed using logistic regression. Stata 12.1 software was used for the analysis. Main Outcome Measures. Reduction in macular central subfield thickness (on spectral-domain OCT) and change in logMAR visual acuity at one month after injection. Results. Lower HbA1c levels (7% or less) were significantly associated with greater reduction in central macular subfield thickness at one month after injection of bevacizumab or ranibizumab on both univariate analysis (p=0.012) and multivariate analysis (p=0.042). Conclusions. Better glycemic control is associated with a greater reduction in central macular thickness after the first injection of bevacizumab or ranibizumab in diabetic macular edema. Patients with high levels of HbA1c and poor response to anti-VEGF may benefit from strict control of their blood glucose.http://dx.doi.org/10.1155/2020/1875860
collection DOAJ
language English
format Article
sources DOAJ
author Wendy Meihua Wong
Caroline Chee
Mayuri Bhargava
Charmaine Chai
Hazel Lin
Paul Zhao
Erlangga Ariadarma Mangunkusumo
Thet Naing
Yew Sen Yuen
Tien Yin Wong
Xinyi Su
Gopal Lingam
spellingShingle Wendy Meihua Wong
Caroline Chee
Mayuri Bhargava
Charmaine Chai
Hazel Lin
Paul Zhao
Erlangga Ariadarma Mangunkusumo
Thet Naing
Yew Sen Yuen
Tien Yin Wong
Xinyi Su
Gopal Lingam
Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
Journal of Ophthalmology
author_facet Wendy Meihua Wong
Caroline Chee
Mayuri Bhargava
Charmaine Chai
Hazel Lin
Paul Zhao
Erlangga Ariadarma Mangunkusumo
Thet Naing
Yew Sen Yuen
Tien Yin Wong
Xinyi Su
Gopal Lingam
author_sort Wendy Meihua Wong
title Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
title_short Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
title_full Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
title_fullStr Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
title_full_unstemmed Systemic Factors Associated with Treatment Response in Diabetic Macular Edema
title_sort systemic factors associated with treatment response in diabetic macular edema
publisher Hindawi Limited
series Journal of Ophthalmology
issn 2090-004X
2090-0058
publishDate 2020-01-01
description Purpose. To identify systemic factors that may influence the response to anti-VEGF therapy in patients with diabetic macular edema (DME). Methods. 35 patients undergoing anti-VEGF injections for centre-involving DME were studied in this prospective observational study. The primary outcome was change in macular thickness one month after treatment, measured using spectral-domain optical coherence tomography (OCT). At baseline, information on various systemic factors was collected including glycosylated hemoglobin (HbA1c), serum VEGF levels, lipid profile and markers of renal function, and blood pressure. Thirty-three of the 35 patients were included in this study. Nonparametric statistical tests were used for the analysis of the data in view of the nonnormal distribution of the outcome variables. Multivariate analysis was performed using logistic regression. Stata 12.1 software was used for the analysis. Main Outcome Measures. Reduction in macular central subfield thickness (on spectral-domain OCT) and change in logMAR visual acuity at one month after injection. Results. Lower HbA1c levels (7% or less) were significantly associated with greater reduction in central macular subfield thickness at one month after injection of bevacizumab or ranibizumab on both univariate analysis (p=0.012) and multivariate analysis (p=0.042). Conclusions. Better glycemic control is associated with a greater reduction in central macular thickness after the first injection of bevacizumab or ranibizumab in diabetic macular edema. Patients with high levels of HbA1c and poor response to anti-VEGF may benefit from strict control of their blood glucose.
url http://dx.doi.org/10.1155/2020/1875860
work_keys_str_mv AT wendymeihuawong systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT carolinechee systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT mayuribhargava systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT charmainechai systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT hazellin systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT paulzhao systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT erlanggaariadarmamangunkusumo systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT thetnaing systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT yewsenyuen systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT tienyinwong systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT xinyisu systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
AT gopallingam systemicfactorsassociatedwithtreatmentresponseindiabeticmacularedema
_version_ 1715316141058949120